Nutlin-3A, a pharmacological inhibitor of the MDM2–p53 interaction, stabilizes p53; however, its clinical efficacy is very low and severe thrombocytopenia represents a dose-limiting toxicity. Here, TP53 is linked to Thrombocytopenia.